

I hereby certify that this paper is being deposited with the U.S. Postal Service as Express Mail, Airbill No. EV 582594845 US, on the date shown below in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Dated: July 26, 2007

Signature: 

(Lori Sims)

Patent
Docket No. 282172002800

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Thomas W. DUBENSKY, Jr. et al.

Examiner: J. Graser

Group Art Unit: 1645

Serial No.: 10/773,618

Filing Date: February 6, 2004

For: MODIFIED FREE-LIVING MICROBES,
VACCINE COMPOSITIONS AND
METHODS OF USE THEREOF

**SUPPLEMENTAL INFORMATION DISCLOSURE
STATEMENT UNDER 37 C.F.R. § 1.97 & 1.98**

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. § 1.97 and § 1.98, Applicants submit for consideration in the above-identified application the documents listed on the attached Form PTO/SB/08a/b. Copies of non-patent literature are submitted herewith. The Examiner is requested to make these documents of record.

This Supplemental Information Disclosure Statement is submitted:

- ☐ With the application; accordingly, no fee or separate requirements are required.
- ☐ Before the mailing of a first Office Action after the filing of a Request for Continued Examination under § 1.114. However, if applicable, a certification under 37 C.F.R. § 1.97 (e)(1) has been provided.

pa-1137163

07/31/2007 HMARZ11 00000000 031952 10773618
02 FC:1006 100.00 DA

- ☐ Within three months of the application filing date or before mailing of a first Office Action on the merits; accordingly, no fee or separate requirements are required. However, if applicable, a certification under 37 C.F.R. § 1.97 (e)(1) has been provided.
- ☒ After receipt of a first Office Action on the merits but before mailing of a final Office Action or Notice of Allowance.
- ☐ A fee is required. A check in the amount of __ is enclosed.
- ☒ A fee is required. Accordingly, a Fee Transmittal form (PTO/SB/17) is attached to this submission in duplicate.
- ☐ A Certification under 37 C.F.R. § 1.97(e) is provided above; accordingly, no fee is believed to be due.
- ☐ After mailing of a final Office Action or Notice of Allowance, but before payment of the issue fee.
- ☐ A Certification under 37 C.F.R. § 1.97(e) is provided above and a check in the amount of __ is enclosed.
- ☐ A Certification under 37 C.F.R. § 1.97(e) is provided above and a Fee Transmittal form (PTO/SB/17) is attached to this submission in duplicate.

Applicants would appreciate the Examiner initialing and returning the Form PTO/SB/08a/b, indicating that the information has been considered and made of record herein.

The information contained in this Supplemental Information Disclosure Statement under 37 C.F.R. § 1.97 and § 1.98 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

In the unlikely event that the transmittal form is separated from this document and the Patent and Trademark Office determines that an extension and/or other relief (such as payment of a fee under 37 C.F.R. § 1.17 (p)) is required, Applicants petition for any required relief including extensions of time and authorize the Commissioner to charge the cost of such petition and/or other

Application Serial No. 10/773,618

Patent
Docket No. 282172002800

fees due in connection with the filing of this document to **Deposit Account No. 03-1952**
referencing **282172002800**.

Dated: July 26, 2007


Respectfully submitted,

By


Alicia J. Hager

Registration No.: 44,140

MORRISON & FOERSTER LLP
755 Page Mill Road
Palo Alto, California 94304-1018
(650) 813-4296



ALTERNATIVE TO PTO/SB/08A/B (09/06)

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			Complete if Known		
			Application Number	10/773,618	
			Filing Date	February 6, 2004	
			First Named Inventor	Thomas W. DUBENSKY, Jr.	
			Art Unit	1645	
			Examiner Name	J. Graser	
Sheet	1	of	8	Attorney Docket Number	282172002800

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
[Handwritten mark]	1.	US-2001/0023072-A1	09-20-2001	Crawford et al.	
	2.	US-2002/0039588-A1	04-04-2002	Collier et al.	
	3.	US-2002/0141977-A1	10-03-2002	Collins et al.	
	4.	US-2002/0155108-A1	10-24-2002	Barbera-Guillem	
	5.	US-2002/0192193-A1	12-19-2002	Chokri et al.	
	6.	US-2003/0092177-A1	05-15-2003	Belardelli et al.	
	7.	US-2003/0119187-A1	06-26-2003	De Santis	
	8.	US-2003/0190682-A1	10-09-2003	Law et al.	
	9.	US-2004/0022761-A1	02-05-2004	Banchereau et al.	
	10.	US-2004/0037807-A1	02-26-2004	Goldman	
	11.	US-2004/0038398-A1	02-26-2004	Crawford et al.	
	12.	US-2005/0175630-A1	08-11-2005	Raz et al.	
	13.	US-2007/0031457-A1	02-08-2007	Dubensky, Jr. et al.	
	14.	US-6,403,080-B1	06-11-2002	Segal	
	15.	US-6,440,735-B1	08-27-2002	Gaeta	
	16.	US-6,497,876-B1	12-24-2002	Maraskovsky et al.	

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)			

*EXAMINER: Initial if information considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		
[Handwritten mark]	17.	Advisory Committee on Immunization Practices. (2001). "Case Report: Use of Anthrax Vaccine in the United States: Recommendations of the Advisory Committee on Immunization Practices," <i>Clinical Toxicology</i> 39(1)85-100.		
	18.	Alonso, J.C. et al. (1991). "Characterization of <i>recF</i> Suppressors in <i>Bacillus subtilis</i> ," <i>Biochimie</i> 73:277-280.		
	19.	Arikan, E. et al. (1986). "Sequences of the <i>E. coli uvrB</i> Gene and Protein," <i>Nucleic Acids Research</i> 14(6):2637-2650.		

Examiner Signature		Date Considered	10/5/07
-----------------------	--	--------------------	---------

pa-1137166

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/773,618
				Filing Date	February 6, 2004
				First Named Inventor	Thomas W. DUBENSKY, Jr.
				Art Unit	1645
				Examiner Name	J. Graser
Sheet	2	of	8	Attorney Docket Number	282172002800

MS Commercial

20.	Armstrong, A.C. et al. (2002). "Cellular Vaccine Therapy for Cancer," <i>Expert. Rev. Vaccines</i> 1(3):303-316.
21.	Asano, K. et al. (May 8, 1998). "Structural Basis for Binding of the Plasmid Col1b-P9 Antisense Inc RNA to Its Target RNA with the 5'-rUUGGCG-3' Motif in the Loop Sequence," <i>J. Biol. Chem.</i> 273(19):11826-11838.
22.	Atalla, A. et al. (August 2003). "The <i>pst</i> Operon of <i>Bacillus subtilis</i> Is Specifically Induced by Alkali Stress," <i>J. Bacteriol.</i> 185(16):5019-5022.
23.	Aulinger, B.A. et al. (June 2005). "Combining Anthrax Vaccine and Therapy: A Dominant-Negative Inhibitor of Anthrax Toxin Is Also a Potent and Safe Immunogen for Vaccines," <i>Infection and Immunity</i> 73(6):3408-3414.
24.	Bahjat, K.S. et al. (November 2006). "Cytosolic Entry Controls CD8+-T-Cell Potency During Bacterial Infection," <i>Infection and Immunity</i> 74(11):6387-6397.
25.	Baillie, L.W.J. et al. (June 1, 1998). "A Heat-Inducible <i>Bacillus subtilis</i> Bacteriophage Φ 105 Expression System for the Production of the Protective Antigen of <i>Bacillus anthracis</i> ," <i>FEMS Microbiol. Lett.</i> 163(1):43-47.
26.	Banchereau, J. et al. (March 19, 1998). "Dendritic Cells and the Control of Immunity," <i>Nature</i> 392(6673):245-252.
27.	Banchereau, J. et al. (September 1, 2001). "Immune and Clinical Responses in Patients with Metastatic Melanoma to CD34+ Progenitor-Derived Dendritic Cell Vaccine," <i>Cancer Res.</i> 61:6451-6458.
28.	Belitsky, B.R. et al. (July 2002). "GabR, A Member of a Novel Protein Family, Regulates the Utilization of γ -Aminobutyrate in <i>Bacillus subtilis</i> ," <i>Mol. Microbiol.</i> 45(2):569-583.
29.	Beverly, M.B. et al. (1996). "A Rapid Approach for the Detection of Dipicolinic Acid in Bacterial Spores Using Pyrolysis/Mass Spectrometry," <i>Rapid Commun. Mass Spectrom.</i> 10:455-458.
30.	Bierne, H. et al. (November 1997). " <i>uvrD</i> Mutations Enhance Tandem Repeat Deletion in the <i>Escherichia coli</i> Chromosome via SOS Induction of the RecF Recombination Pathway," <i>Mol. Microbiol.</i> 26(3):557-567.
31.	Brockstedt, D.G. et al. (September 21, 2004). "Listeria-based Cancer Vaccines That Segregate Immunogenicity From Toxicity," Supporting Information, Table and Figures, <i>Proc. Natl. Acad. Sci. USA Data Supplement</i> located at http://www.pnas.org/cgi/content/full/0406035101/DC1 , last visited on July 22, 2007, 9 pages.
32.	Brown, D.P. et al. (November 1994). "Characterization of <i>spo0A</i> Homologues in Diverse <i>Bacillus</i> and <i>Clostridium</i> Species Identifies a Probable DNA-Binding Domain," <i>Mol. Microbiol.</i> 14(3):411-426.
33.	Bruno, J.G. et al. (1999). "In Vitro Selection of DNA Aptamers to Anthrax Spores with Electrochemiluminescence Detection," <i>Biosens. Bioelectron.</i> 14:457-464.
34.	Campoy, S. et al. (November 2002). "A New Regulatory DNA Motif of the Gamma Subclass <i>Proteobacteria</i> : Identification of the LexA Protein Binding Site of the Plant Pathogen <i>Xylella fastidiosa</i> ," <i>Microbiology</i> 148:3583-3597.
35.	Carl, M. et al. (June 1992). "Detection of Spores of <i>Bacillus anthracis</i> Using the Polymerase Chain Reaction," <i>J. Infect. Dis.</i> 165(6):1145-1148.

Examiner
Signature

pa- 1137166

Date
Considered

10/5/07

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/773,618
				Filing Date	February 6, 2004
				First Named Inventor	Thomas W. DUBENSKY, Jr.
				Art Unit	1645
				Examiner Name	J. Graser
Sheet	3	of	8	Attorney Docket Number	282172002800

36.	Carrasco, B. et al. (2002). "Effect of the <i>recU</i> Suppressors <i>sms</i> and <i>subA</i> on DNA Repair and Homologous Recombination in <i>Bacillus subtilis</i> ," <i>Mol. Genet. Genomics</i> 266:899-906.
37.	Chan, A.Y. et al. (October 10, 2003). "Interaction of a Putative Transcriptional Regulatory Protein and the Thermo-Inducible <i>cts-52</i> Mutant Repressor in the <i>Bacillus subtilis</i> Phage ϕ 105 Genome," <i>J. Mol. Biol.</i> 333(1):21-31.
38.	Chang, D.H. et al. (June 2003). "Dendritic Cells and Immunotherapy for Cancer," <i>Int. J. Hematol.</i> 77(5):439-443.
39.	Clark, A.J. (1991). " <i>rec</i> Genes and Homologous Recombination Proteins in <i>Escherichia coli</i> ," <i>Biochemie</i> 73:523-532.
40.	Coote, J.G. et al. (January 1996). "A Rapid, Colourimetric Assay for Cytotoxin Activity in <i>Campylobacter jejuni</i> ," <i>FEMS Immunol. Med. Microbiol.</i> 13(1):65-70.
41.	Courcelle, J. et al. (July 17, 2001). "Participation of Recombination Proteins in Rescue of Arrested Replication Forks in UV-Irradiated <i>Escherichia coli</i> Need Not Involve Recombination," <i>Proc. Natl. Acad. Sci. USA</i> 98(15):8196-8202.
42.	Crowley, D.J. et al. (May 10, 2001). "The SOS-Dependent Upregulation of <i>uvrD</i> is not Required for Efficient Nucleotide Excision Repair of Ultraviolet Light Induced DNA Photoproducts in <i>Escherichia coli</i> ," <i>Mutat. Res.</i> 485(4):319-329.
43.	Davis, E.O. et al. (June 2002). "Definition of the Mycobacterial SOS Box and Use To Identify LexA-Regulated Genes in <i>Mycobacterium tuberculosis</i> ," <i>J. Bacteriol.</i> 184(12):3287-3295.
44.	Deuerling, E. et al. (July 1995). "The <i>fisH</i> Gene of <i>Bacillus subtilis</i> Is Transiently Induced after Osmotic and Temperature Upshift," <i>J. Bacteriol.</i> 177(14):4105-4112.
45.	Dhodapkar, M.V. et al. (May 2000). "Active Immunization of Humans with Dendritic Cells," <i>J. Clin. Immunol.</i> 20(3):167-174.
46.	Drago, L. et al. (November 2002). "Real-Time PCR Assay for Rapid Detection of <i>Bacillus anthracis</i> Spores in Clinical Samples," <i>J. Clin. Microbiol.</i> 40(11):4399.
47.	Drevets, D.A. (January 1998). " <i>Listeria monocytogenes</i> Virulence Factors That Stimulate Endothelial Cells," <i>Infection and Immunity</i> 66(1):232-238.
48.	Dullaghan, E.M. et al. (November 2002). "The Role of Multiple SOS Boxes Upstream of the <i>Mycobacterium tuberculosis</i> <i>lexA</i> Gene - Identification of a Novel DNA-Damage-Inducible Gene," <i>Microbiology</i> 148(11):3609-3615.
49.	Esche, C. et al. (February 1999). "The Use of Dendritic Cells for Cancer Vaccination," <i>Curr. Opin. Mol. Ther.</i> 1(1):72-81.
50.	Fisher, S.H. (April 1999). "Regulation of Nitrogen Metabolism in <i>Bacillus subtilis</i> : vive la différence!" <i>Mol. Microbiol.</i> 32(2):223-232.
51.	Fouet, A. et al. (2002). " <i>Bacillus anthracis</i> Cell Envelope Components" Chapter 5 In <u>Current Topics In Microbiology and Immunology</u> , Compans, R.W. et al. eds., Springer-Verlag: Germany, 271:87-113.
52.	Franklin, W.A. et al. (June 1984). "Removal of UV Light-Induced Pyrimidine-Pyrimidone(6-4) Products from <i>Escherichia coli</i> DNA Requires the <i>uvrA</i> , <i>uvrB</i> , and <i>uvrC</i> Gene Products," <i>Proc. Natl. Acad. Sci. USA</i> 81(12):3821-3824.

Examiner Signature	Date Considered
--------------------	-----------------

pa-1137166

not considered

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			Complete if Known		
			Application Number	10/773,618	
			Filing Date	February 6, 2004	
			First Named Inventor	Thomas W. DUBENSKY, Jr.	
			Art Unit	1645	
			Examiner Name	J. Graser	
Sheet	4	of	8	Attorney Docket Number	282172002800

53.	Fuangthong, M. et al. (June 2002). "Regulation of the <i>Bacillus subtilis</i> <i>fur</i> and <i>perR</i> Genes by PerR: Not All Members of the PerR Regulon Are Peroxide Inducible," <i>J. Bacteriol.</i> 184(12):3276-3286.
54.	GenBank Accession No. AF268967, created July 31, 2000, located at < http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=9280532 >, last visited on May 16, 2007, three pages.
55.	GenBank Accession No. AF306778, created October 1, 2003, located at < http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=10880942 >, last visited on May 16, 2007, two pages.
56.	GenBank Accession No. AJ271621, created November 14, 2006, located at < http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&id=27527036 >, last visited on June 30, 2007, four pages.
57.	GenBank Accession No. AJ409321, created April 15, 2005, located at < http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=40643279 >, last visited on July 22, 2007, two pages.
58.	GenBank Accession No. AY700758, created November 21, 2005, located at < http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=51235129 >, last visited on May 16, 2007, two pages.
59.	Genbank Accession No. AY997299, created April 26, 2005, located at < http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=62823103 >, last visited on May 16, 2007, two pages.
60.	Genbank Accession No. NC_007530, created April 3, 2006, located at < http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=50196905 >, last visited on May 16, 2007, 163 pages.
61.	GenBank Accession No. V00328, created April 18, 2005, located at < http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=42672 >, last visited on May 16, 2007, three pages.
62.	GenBank Accession No. X81135, created November 30, 2006, located at < http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=16735862 >, last visited on July 22, 2007, three pages.
63.	Griffiths, A.J.F. et al. (1999). <i>Modern Genetic Analysis: Integrating Genes and Genomes</i> , Second Edition, W.H. Freeman and Company, New York, NY, pg. 315.
64.	Guidi-Rontani, C. et al. (July 1999). "Identification and Characterization of a Germination Operon on the Virulence Plasmid pXOI of <i>Bacillus anthracis</i> ," <i>Mol. Microbiol.</i> 33(2):407-414.
65.	Haddad, E.E. et al. (October-December 1994). "Adaptation of the MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyl Tetrazolium Bromide) Assay for the Determination of Virus-Neutralizing Antibodies Using the Virus-Neutralization Assay," <i>Avian Dis.</i> 38(4):755-761.
66.	Hall, J.D. et al. (March 1975). "Temperature-Sensitive <i>recA</i> Mutant of <i>Escherichia coli</i> K-12: Deoxyribonucleic Acid Metabolism After Ultraviolet Irradiation," <i>J. Bacteriol.</i> 121(3):892-900.
67.	Hanna, M.N. et al. (October 2001). " <i>uvrA</i> is an Acid-Inducible Gene Involved in the Adaptive Response to Low pH in <i>Streptococcus mutans</i> ," <i>J. Bacteriol.</i> 183(20):5964-5973.

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

pa-1137166

not considered

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known			
		Application Number	10/773,618		
		Filing Date	February 6, 2004		
		First Named Inventor	Thomas W. DUBENSKY, Jr.		
		Art Unit	1645		
		Examiner Name	J. Graser		
Sheet	5	of	8	Attorney Docket Number	282172002800

68.	Hartley, H.A. et al. (June 2003). "Biosensor for the Specific Detection of a Single Viable <i>B. anthracis</i> Spore," <i>Analy. Bioanal. Chem.</i> 376(3):319-327.
69.	Hecker, M. et al. (February 1996). "Heat-Shock and General Stress Response in <i>Bacillus subtilis</i> ," <i>Mol. Microbiol.</i> 19(3):417-428.
70.	Hering, D. et al. (March 2004). "Validation of the Anthrax Lethal Toxin Neutralization Assay," <i>Biologicals</i> 32(1):17-27.
71.	Hilbert, D.W. et al. (March 2003). "Novel <i>spoIIIE</i> Mutation That Causes Uncompartmentalized σ^F Activation in <i>Bacillus subtilis</i> ," <i>J. Bacteriol.</i> 185(5):1590-1598.
72.	Humrich, J. et al. (2003). "Viral Vectors for Dendritic Cell-Based Immunotherapy," Chapter 11 In <i>Dendritic Cells and Virus Infection</i> , Steinkasserer, A. ed., Springer-Verlag: Germany, 276:241-259.
73.	Husain, I. et al. (April 15, 1986). "Sequences of <i>Escherichia coli</i> <i>uvrA</i> Gene and Protein Reveal Two Potential ATP Binding Sites," <i>The Journal of Biological Chemistry</i> 261(11):4895-4901.
74.	Ivánovics, G. (1962). "The Pathogenicity of <i>Bacillus anthracis</i> Lysogenic with Mutants of Phage W," <i>J. Gen. Microbiol.</i> 28:87-101.
75.	Johansson, J. et al. (June 2003). "RNA-Mediated Control of Virulence Gene Expression in Bacterial Pathogens," <i>Trends Microbiol.</i> 11(6):280-285.
76.	Johnston, J.L. et al. (March 1997). "The <i>RecA</i> Gene from <i>Clostridium perfringens</i> is Induced by Methyl Methanesulphonate and Contains an Upstream Chea Box," <i>Microbiology</i> 143(3):885-890.
77.	Kaan, T. et al. (November 2002). "Genome-Wide Transcriptional Profiling of the <i>Bacillus subtilis</i> Cold-Shock Response," <i>Microbiol.</i> 148(11):3441-3455.
78.	Karginov, V.A. et al. (January 15, 2004). "Treatment of Anthrax Infection with Combination of Ciprofloxacin and Antibodies to Protective Antigen of <i>Bacillus anthracis</i> ," <i>FEMS Immunol. Med. Microbiol.</i> 40(1):71-74.
79.	Kawai, Y. et al. (February 2003). "Identification of a Protein, YneA, Responsible for Cell Division Suppression During the SOS Response in <i>Bacillus subtilis</i> ," <i>Mol. Microbiol.</i> 47(4):1113-1122.
80.	King, D. et al. (July 2003). "Performance Assessment of Three Commercial Assays for Direct Detection of <i>Bacillus anthracis</i> Spores," <i>J. Clin. Microbiol.</i> 41(7):3454-3455.
81.	Kuzminov, A. (December 1999). "Recombinational Repair of DNA Damage in <i>Escherichia coli</i> and Bacteriophage λ ," <i>Microbiol. Mol. Biol. Rev.</i> 63(4):751-813.
82.	Lecuit, M. (December 1997). "Internalin of <i>Listeria monocytogenes</i> with an Intact Leucine-Rich Repeat Region Is Sufficient To Promote Internalization," <i>Infection and Immunity</i> 65(12):5309-5319.
83.	Lin, J.-J. et al. (December 5, 1990). "Reconstitution of Nucleotide Excision Nuclease with UvrA and UvrB Proteins from <i>Escherichia coli</i> and UvrC Protein from <i>Bacillus subtilis</i> ," <i>J. Biol. Chem.</i> 265(34):21337-21341.
84.	Lin, L. et al. (May 1, 1994). "Photochemical Inactivation of Pathogenic Bacteria in Human Platelet Concentrates," <i>Blood</i> 83(9):2698-2706.
85.	Lingnau, A. et al. (October 1995). "Expression of the <i>Listeria monocytogenes</i> <i>EGD</i> , <i>inlA</i> and <i>inlB</i> Genes, Whose Products Mediate Bacterial Entry into Tissue Culture Cell Lines, by PrfA-Dependent and -Independent Mechanisms," <i>Infection and Immunity</i> 63(10):3896-3903.

Examiner Signature	Date Considered
--------------------	-----------------

pa-1137166

not Considered

Substitute for form 1449/PTO				Complete if Known	
				Application Number	10/773,618
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Filing Date	February 6, 2004
				First Named Inventor	Thomas W. DUBENSKY, Jr.
				Art Unit	1645
				Examiner Name	J. Graser
Sheet	6	of	8	Attorney Docket Number	282172002800

86.	Lipman, D.J. (September 15, 1997). "Making (Anti)Sense of Non-Coding Sequence Conservation," <i>Nucleic Acids Res.</i> 25(18):3580-3583.	
87.	Little, S.F. et al. (2004). "Defining a Serological Correlate of Protection in Rabbits for a Recombinant Anthrax Vaccine," <i>Vaccine</i> 22:422-430.	
88.	Liu, J. et al. (December 1, 2003). "Computational Identification of the Spo0A-Phosphate Regulon That is Essential for the Cellular Differentiation and Development in Gram-Positive Spore-Forming Bacteria," <i>Nucleic Acids Res.</i> 31(23):6891-6903.	
89.	Lovett, C.M. et al. (November 1993). "Purification of an SOS Repressor from <i>Bacillus subtilis</i> ," <i>J. Bacteriol.</i> 175(21):6842-6849.	
90.	Lovett, C.M. Jr. et al. (August 1994). "Analysis of the SOS Inducing Signal in <i>Bacillus subtilis</i> using <i>Escherichia coli</i> LexA as a Probe," <i>J. Bacteriol.</i> 176(16):4914-4923.	
91.	Lu, W. et al. (January 2003). "Therapeutic Dendritic-Cell Vaccine for Simian AIDS," <i>Nature Medicine</i> 9(1):27-32.	
92.	Mao, J-R. et al. (August 25, 1995). "Gene Regulation by Antisense DNA Produced <i>in Vivo</i> ," <i>J. Biol. Chem.</i> 270(34):19684-19687.	
93.	McGuire, A.M. et al. (May 2000). "Conservation of DNA Regulatory Motifs and Discovery of New Motifs in Microbial Genomes," <i>Genome Res.</i> 10(5):744-757.	
94.	Meletiadiis, J. et al. (August 2000). "Comparison of NCCLS and 3-(4,5-Dimethyl-2-Thiazyl)-2,5-Diphenyl-2H-Tetrazolium Bromide (MTT) Methods of In Vitro Susceptibility Testing of Filamentous Fungi and Development of a New Simplified Method," <i>J. Clin. Microbiol.</i> 38(8):2949-2954.	
95.	Mengaud, J. et al. (March 22, 1996). "E-Cadherin Is the Receptor for Internalin, a Surface Protein Required for Entry of <i>L. monocytogenes</i> into Epithelial Cells," <i>Cell</i> 84:923-932.	
96.	Mesnager, S. et al. (January 1998). "The Capsule and S-Layer: Two Independent and Yet Compatible Macromolecular Structures in <i>Bacillus anthracis</i> ," <i>J. Bacteriol.</i> 180(1):52-58.	
97.	Miller, M.C. et al. (December 27, 1996). "The <i>Bacillus subtilis</i> <i>dinR</i> Gene Codes for the Analogue of <i>Escherichia coli</i> LexA," <i>J. Biol. Chem.</i> 271(52):33502-33508.	
98.	Mongkolsuk, S. et al. (July 2002). "Regulation of Inducible Peroxide Stress Responses," <i>Mol. Microbiol.</i> 45(1):9-15.	
99.	Mota, L.J. et al. (July 2001). "Control of the Arabinose Regulon in <i>Bacillus subtilis</i> by AraR <i>In Vivo</i> : Crucial Roles of Operators, Cooperativity, and DNA Looping," <i>J. Bacteriol.</i> 183(4):4190-4201.	
100.	Mourez, M. et al. (October 2001). "Designing a Polyvalent Inhibitor of Anthrax Toxin," <i>Nature Biotech.</i> 19(10):958-961.	
101.	Movahedzadeh, F. et al. (March 1997). "Characterization of <i>Mycobacterium tuberculosis</i> LexA: Recognition of a Cheo (<i>Bacillus</i> -type SOS) Box," <i>Microbiology</i> 143(3):929-936.	
102.	Mu, D. et al. (1997). "DNA Excision Repair Assays" <i>In Progress in Nucleic Acid Research and Molecular Biology</i> , Cohn, W.E. et al. eds., Academic Press, Inc.: San Diego, CA, 56:63-81.	
103.	Munakata, N. et al. (November 1991). "Inactivation Action Spectra of <i>Bacillus subtilis</i> Spores in Extended Ultraviolet Wavelengths (50-300 nm) Obtained with Synchrotron Radiation," <i>Photochem. Photobiol.</i> 54(5):761-768.	

Examiner Signature	Date Considered
--------------------	-----------------

pa- 1137166


not considered

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/773,618
				Filing Date	February 6, 2004
				First Named Inventor	Thomas W. DUBENSKY, Jr.
				Art Unit	1645
				Examiner Name	J. Graser
Sheet	7	of	8	Attorney Docket Number	282172002800

104.	Nickel, M. et al. (August 2004). "Cold Induction of the <i>Bacillus subtilis</i> <i>bkd</i> Operon is Mediated by Increased mRNA Stability," <i>Mol. Genet. Genomics</i> 272(1):98-107.	
105.	Noone, D. et al. (March 2000). "Expression of <i>ykda</i> , Encoding a <i>Bacillus subtilis</i> Homologue of HtrA, Is Heat Shock Inducible and Negatively Autoregulated," <i>J. Bacteriol.</i> 182(6):1592-1599.	
106.	Office Action mailed January 31, 2007, for U.S. Application No. 10/773,792, filed February 6, 2004, 20 pages.	
107.	Office Action mailed March 8, 2007, for U.S. Application No. 10/883,599, filed June 30, 2004, 6 pages.	
108.	Palucka, A.K. et al. (September/October 2003). "Single Injection of CD34+ Progenitor-Derived Dendritic Cell Vaccine Can Lead to Induction of T-Cell Immunity in Patients With Stage IV Melanoma," <i>J. Immunother.</i> 26(5):432-439.	
109.	Pombo, M. et al. (September 2004). "Validation of an Anti-PA-ELISA for the Potency Testing of Anthrax Vaccine in Mice," <i>Biologicals</i> 32(3):157-163.	
110.	Ramaswamy, M. et al. (January 7, 1994). "Sequence-Specific Interactions of UvrABC Endonuclease with Psoralen Interstrand Cross-Links," <i>J. Biol. Chem.</i> 269(1):485-492.	
111.	Repoila, F. et al. (November 2003). "Temperature Sensing by the <i>dsrA</i> Promoter," <i>J. Bacteriol.</i> 185(22):6609-6614.	
112.	Sakamoto, T. et al. (February 2002). "Regulation of the Desaturation of Fatty Acids and its Role in Tolerance to Cold and Salt Stress," <i>Curr. Opin. Microbiol.</i> 5(1):206-210.	
113.	Sancar, A. (1996). "DNA Excision Repair," <i>Annu. Rev. Biochem.</i> 65:43-81.	
114.	Santini, S.M. et al. (2003). "Advances in the Use of Dendritic Cells and New Adjuvants for the Development of Therapeutic Vaccines," <i>Stem Cells</i> 21(4):495-505.	
115.	Schofield, D.A. et al. (June 2003). "Development of a Thermally Regulated Broad-Spectrum Promoter System for Use in Pathogenic Gram-Positive Species," <i>Appl. Environ. Microbiol.</i> 69(6):3385-3392.	
116.	Schönert, S. et al. (April 1999). "Properties of Maltose-Inducible α -Glucosidase Mall (Sucrase-Isomaltase-Maltase) in <i>Bacillus subtilis</i> : Evidence for its Contribution to Maltodextrin Utilization," <i>Res. Microbiol.</i> 150(3):167-177.	
117.	Schuler, G. et al. (April 2003). "The Use of Dendritic Cells in Cancer Immunotherapy," <i>Curr. Opin. Immunol.</i> 15(2):138-147.	
118.	Sellman, B.R. et al. (March 16, 2001). "Point Mutations in Anthrax Protective Antigen That Block Translocation," <i>J. Biol. Chem.</i> 276(11):8371-8376.	
119.	Sellman, B.R. et al. (April 27, 2001). "Dominant-Negative Mutants of a Toxin Subunit: An Approach to Therapy of Anthrax," <i>Science</i> 292(5517):695-697.	
120.	Sölke, J. et al. (July 1997). "Induction of the <i>Bacillus subtilis</i> <i>ptsGHI</i> Operon by Glucose is Controlled by a Novel Antiterminator, GlcT," <i>Mol. Microbiol.</i> 25(1):65-78.	
121.	Thorne, C.B. (July 1968). "Transducing Bacteriophage for <i>Bacillus cereus</i> ," <i>J. Virology</i> 2(7):657-662.	
122.	Wagner, E.G.H. et al. (1994). "Antisense RNA Control in Bacteria, Phages, and Plasmids," <i>Ann. Rev. Microbiol.</i> 48:713-742.	
123.	Walsh, S.R. et al. (April 2003). "Dendritic Cells and the Promise of Therapeutic Vaccines for Human Immunodeficiency Virus (HIV)-1," <i>Curr. HIV Res.</i> 1:205-216.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

pa- 1137166



Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/773,618
				Filing Date	February 6, 2004
				First Named Inventor	Thomas W. DUBENSKY, Jr.
				Art Unit	1645
				Examiner Name	J. Graser
Sheet	8	of	8	Attorney Docket Number	282172002800

124.	Wang, B. et al. (March 28, 2003). "Assessment of the Utilization of the Antisense RNA Strategy to Identify Essential Genes in Heterologous Bacteria," <i>FEMS Microbiol. Lett.</i> 220(2):171-176.	
125.	Winterling, K.W. et al. (March 1997). "Characterization of DinR, the <i>Bacillus subtilis</i> SOS Repressor," <i>J. Bacteriol.</i> 179(5):1698-1703.	
126.	Wong, K.K.Y. et al. (2004). "Evidence Implicating the 5' Untranslated Region of <i>Listeria monocytogenes actA</i> in the Regulation of Bacterial Actin-Based Motility," <i>Cellular Microbiology</i> 6(2):155-166.	
127.	World Health Organization. (1970). <u>Health Aspects of Chemical and Biological Weapons: A Report of a WHO Group of Consultants</u> , World Health Organization: Geneva, Switzerland, pp. 5 - 7 (Table of Contents Only.)	
128.	Worsham, P.L. et al. (January 1999). "Isolation of an Asporogenic (<i>spoOA</i>) Protective Antigen-Producing Strain of <i>Bacillus anthracis</i> ," <i>Can. J. Microbiol.</i> 45(1):1-8.	
129.	Yan, M. et al. (January/February 2003). "Characterization of Dominant-Negative Forms of Anthrax Protective Antigen," <i>Molecular Medicine</i> pp. 46-51.	
130.	Yansura, D.G. et al. (January 1984). "Use of the <i>Escherichia coli lac</i> Repressor and Operator to Control Gene Expression in <i>Bacillus subtilis</i> ," <i>Proc. Natl. Acad. Sci USA</i> 81(2):439-443.	
131.	Yasbin, R.E. et al. (May 1992). "Inducible DNA Repair and Differentiation in <i>Bacillus subtilis</i> : Interactions Between Global Regulons," <i>Mol. Microbiol.</i> 6(10):1263-1270.	
132.	Zhang, X. et al. (November 6, 2002). "Advances in Dendritic Cell-Based Vaccine of Cancer," <i>Cancer Biother./Radiopharm.</i> 17(6):601-619.	
133.	Zhou, B. et al. (April 16, 2002). "Human Antibodies Against Spores of the Genus <i>Bacillus</i> : A Model Study for Detection of and Protection Against Anthrax and the Bioterrorist Threat," <i>Proc. Natl. Acad. Sci. USA</i> 99(8):5241-5246.	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

pa-1137166

not considered